UNIKUM Therapeutics ApS
CVR 41192925 · Private limited company (ApS) · Active · Medium risk
UNIKUM Therapeutics ApS is a Private limited company (ApS), founded on , based in Risskov. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 2.6% over the next 12 months, which is 1.9 times the average for Danish companies. 6 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK -5.7m and a net result of DKK -859k. CEO: Martin Roelsgaard Jakobsen.
Bankruptcy risk for UNIKUM Therapeutics ApS
1.9 × the average (1.41%) · higher risk than 86% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 41192925
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (6 years)
- Address
- c/o Martin Jakobsen, Kanehaven 33
8240 Risskov - Municipality
- Aarhus
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 89k
- Audit opted out
- Yes
Warning signs
| Annual reports filed late | 0 of 6 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -4,119.0% |
| Current ratio | 44% |
| Moves (last 2 years) | 1 |
| CEO changes in total | 6 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 1 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -248k | DKK -7.4m |
| Net profit | DKK -859k | DKK -13.8m |
| Equity | DKK -5.7m | DKK -4.8m |
| Total assets | DKK 138k | DKK 3.8m |
| Cash | DKK 72k | – |
| Short-term debt | DKK 311k | – |
| Avg. employees | 0 | – |
Latest annual report: Reporting class B · auditor's statement: No audit assistance.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 70 | ||
| 1 Jan 2024 – 31 Dec 2024 | 147 | ||
| 1 Jan 2023 – 31 Dec 2023 | 85 | ||
| 1 Jan 2022 – 31 Dec 2022 | 131 | ||
| 1 Jan 2021 – 31 Dec 2021 | 110 | ||
| 17 Feb 2020 – 31 Dec 2020 | 151 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Martin Roelsgaard Jakobsen | Current | |
| CEO | Søren Sylvester Skjærbæk | ||
| CEO | Rasmus Otkjær Bak | ||
| CEO | Tommi Petteri Kainu | ||
| Board | Martin Roelsgaard Jakobsen | Current | |
| Board | Ulrik Bjerl Nielsen | Current | |
| Board | Stefan Wildt | Current | |
| Board | Johannes Heinrich Frühauf | ||
| Board | Nebojsa Milovic | ||
| Board | Margo Rosemary Roberts | ||
| Owner (5%) | MEDIC ADVICE ApS | Current | |
| Owner (5%) | RO Bak Holding ApS | Current | |
| Owner (33%) | Volnay Therapeutics, LLC | Current | |
| Owner (5%) | BII Holdings A/S | Current | |
| Owner (15%) | MR Jakobsen Holding ApS | Current | |
| Owner (5%) | Ulrik Bjerl Nielsen | ||
| Owner (10%) | MEDIC ADVICE ApS | ||
| Owner (5%) | ZOCCA CONSULTING ApS | ||
| Owner (33%) | MR Jakobsen Holding ApS | ||
| Owner (10%) | RO Bak Holding ApS | ||
| Owner (10%) | Anders Laustsen Holding ApS | ||
| Owner (5%) | Fallingwater Capital ApS | ||
| Owner (5%) | Ulrik Bjerl Nielsen | ||
| Owner (10%) | MEDIC ADVICE ApS | ||
| Owner (33%) | MR Jakobsen Holding ApS | ||
| Owner (10%) | RO Bak Holding ApS | ||
| Owner (5%) | Anders Laustsen Holding ApS | ||
| Owner (5%) | UNIKUM Therapeutics ApS | ||
| Owner (10%) | Volnay Therapeutics, LLC | ||
| Owner (25%) | MR Jakobsen Holding ApS | ||
| Owner (25%) | Volnay Therapeutics, LLC | ||
| Owner (20%) | MR Jakobsen Holding ApS | ||
| Owner (5%) | BioInnovation Institute Fonden | ||
| Founder | Ulrik Bjerl Nielsen | Current | |
| Founder | MEDIC ADVICE ApS | Current | |
| Founder | ZOCCA CONSULTING ApS | Current | |
| Founder | MR Jakobsen Holding ApS | Current | |
| Founder | RO Bak Holding ApS | Current | |
| Founder | Anders Laustsen Holding ApS | Current |
The CEOs' other companies
Martin Roelsgaard Jakobsen – 3 other companies, of which 1 bankrupt
- STIPE Therapeutics ApS Bankrupt 3 Feb 2026
- MR Jakobsen Holding ApS Active
- Sulis Therapeutics ApS Active
Søren Sylvester Skjærbæk – 12 other companies, of which 1 bankrupt
- LEDBANNER A/S Bankrupt 16 Sep 2010
- ACTAS A/S Active
- Akylox Therapeutics ApS Active
- BIOMEDICOS A/S Compulsorily dissolved
- HyperBio Therapeutics ApS Opløst
- JOMS ApS Active
- Life Science Legal ApS Active
- NSEXPLORER A/S Opløst
- NSGENE A/S Opløst
- Orbis Medicines ApS Active
- RheumaLogics ApS Active
- SOJA ApS Opløst
Rasmus Otkjær Bak – 1 other companies
- RO Bak Holding ApS Active
Tommi Petteri Kainu – 2 other companies
- Fallingwater Capital ApS Active
- GlyProVac ApS Active
Address history (1 moves)
| c/o Martin Jakobsen, Kanehaven 33, 8240 Risskov | |
| Ole Maaløes Vej 3, 2200 København N |
Other companies at the same address
- MR Jakobsen Holding ApS Active
Similar companies in Aarhus
- Resiliency Centre ApS Aarhus N
- SymbioMatch ApS Aarhus C
- AptaShape ApS Aarhus C
- Aptamist ApS Lystrup
- Mmimetika ApS Aarhus N
- MKR Finans APS Aarhus C
- Cystotech ApS Aarhus C
- IMCOR ApS Egå
- Commit Biologics ApS Aarhus C
- Økologisk Komplementarselskab ApS Aarhus N
- MyGold ApS Aarhus C
- Solsten Diagnostics International ApS Aarhus N
Questions and answers about UNIKUM Therapeutics ApS
Has UNIKUM Therapeutics ApS gone bankrupt?
No, UNIKUM Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of UNIKUM Therapeutics ApS?
Our model estimates a bankruptcy risk of 2.6% over the next 12 months (medium risk), which is 1.9 times the average for Danish companies.
Who is the CEO of UNIKUM Therapeutics ApS?
Martin Roelsgaard Jakobsen is the CEO of UNIKUM Therapeutics ApS.
When was UNIKUM Therapeutics ApS founded?
UNIKUM Therapeutics ApS was founded on 17 February 2020.
What is the equity of UNIKUM Therapeutics ApS?
Equity was DKK -5.7m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.